Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
We haven't written up this one. Channel News Asia has the full story — the link below goes straight to it.
More in AI
Nvidia’s Jensen Huang brings ‘sovereign AI’ push to Kazakhstan, shrugs off bubble fears
Nvidia CEO Jensen Huang is pitching the concept of “sovereign AI” in Kazakhstan – part of his global crusade urging nations to build domestic computing infrastructure using the firm’s chips – as the…
This 3.5%-Yielding Dividend Stock is Betting Another $5.4 Billion to Help Fuel the AI Power Revolution
Kinder Morgan continues to secure new expansion projects.
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
AI drug firm Pathos raises $237 million, a deal that brings together a big Tempus dataset, AI analysis from Pathos, and drug development from BMS.
Ukraine hits Russian data centres in blow to Moscow's AI capabilities
Drones hit three Yandex facilities, a Sber centre and a VKontakte server farm across five Russian regions, causing persistent failures in payments, navigation and cloud services.
Oncology Needs Living Evidence, Not More AI Summaries | Opinion
AI could keep cancer evidence current, but clinical tools must be validated, traceable and governed by qualified experts.
- Precision oncology increases treatment options but complicates evidence management.
- Oncologists must consult multiple sources, leading to fragmented evidence infrastructure.
- AI should create systems to continuously update and maintain evidence for treatment decisions.